as soon as possible after surgery which increases the metabolic demand. 19 There is a high risk of postoperative anaemia, even among preoperatively non-anaemic patients. 15 20 Apart from blood loss, inflammatory processes associated with surgery can substantially affect Hb levels via impairment of iron homeostasis. 21 22 Pro-inflammatory cytokines (e.g.
IL-6, TNF-a) can increase hepcidin-expression which deactivates the iron export protein ferroportin and leads to iron sequestration in enterocytes and macrophages, a condition known as functional iron deficiency. 22 Accordingly, postoperative anaemia in lower limb arthroplasty has often a multifactorial history of preoperative anaemia ( 25%), 3 blood loss ( 30% of volume), 23 and iron deficiency. Thus, rapid iron substitution, as recommended for preoperative anaemia management, 24 -26 should also be considered after operation. 26 -28 Although, depending on the timescale before surgery, oral iron is suggested for preoperatively anaemic patients with absolute iron deficiency, 24 -26 oral iron showed no benefit over placebo in anaemic patients after lower limb arthroplasty. 29 In patients at risk of functional iron deficiency due to chronic inflammation of different aetiologies, i.v. iron administration has proven its superiority over oral iron. 30 Even in iron-deficient patients without established anaemia, i.v. iron improved physical performance and cardiac functional class. 31 Thus, postoperative anaemia treatment with i.v. iron might not only reduce RBC requirements but also improve performance, rehabilitation, and outcomes. 32 The aim of this study was to compare the efficacy of postoperative i.v. ferric carboxymaltose (FCM) and oral ferrous glycine sulphate (FS) for early improvement of postoperative anaemia after TKA and recovery from surgery.
Methods

Study design
This study was designed as a prospective, single-blinded, randomized, controlled trial of patients who underwent TKA at the University Hospital Mar-Esperança, Barcelona, Spain. It was performed from January 2011 to January 2012 in compliance with the Declaration of Helsinki and the Guideline of Good Clinical Practice, registered (EudraCT 2010-023038-22, ClinicalTrials.gov NCT01913808), and approved by the hospital's independent ethics committee.
Patients
Adult patients (≥18 yr of age) were recruited at the scheduled preoperative visit (21 -30 days prior to surgery). Patients with known hypersensitivity or contraindications to iron, liver insufficiency (aspartate aminotransferase or alanine aminotransferase .60 IU litre 21 ), bronchial asthma, presence of acute or chronic infection, severe heart disease, significant history of allergies (rash, etc.), or anti-anaemia treatment within 15 days before surgery were excluded from participation. Also pregnant or nursing women were excluded (negative pregnancy urine test within 7 days prior first study treatment or amenorrhoea for at least 12 months).
After signing informed consent, patients had aspects of their quality of life (EQ-5D questionnaire), independence in daily activities (Barthel Index), and physical performance [6 min walk test (6-MWT)] measured.
Perioperative patient management
Preoperative PBM included anaemia assessment 1 month before surgery. Anaemic patients were treated with iron, subcutaneous erythropoietin, or both according to the institutional standard protocol (Fig. 1) . Patients received spinal anaesthesia unless contraindicated. Antithrombotic treatment was initiated 6 h after operation (subcutaneous bemiparin 3500 IU day
21
). During surgery, the patients could receive a dose of 1000 mg tranexamic acid before tourniquet release at the anaesthesiologist's discretion. After operation, patients were equipped with an autotransfusion device (Bellovag ABT, Wellspect HealthCare, Mölndal, Sweden) for reinfusion of shed blood if the collected volume exceeded 400 ml. Analgesia was initiated in the immediate postoperative period, and comprised femoral and sciatic block supplemented with i.v. analgesics according to the institutional protocol. From 48 h after surgery, patients received conventional oral analgesia. Triggers of RBC transfusions were Hb ,8.0 g dl 21 or occurrence of acute anaemia symptoms (e.g. dizziness, chest pain, tachycardia, persistent hypotension). Drugs used for the control of surgery-related symptoms were permitted unless investigators considered the drug to influence the study endpoints (e.g. doxycillin in the FS group).
Randomization, blinding, and intervention
On the day after surgery, eligible patients with anaemia (Hb ,12 g dl
21
), iron deficiency [transferrin saturation (TSAT) ,20%], or both were randomly assigned 1:1 to receive either i.v. FCM or oral FS. Randomization was performed using a random number list that had been electronically generated before initiation of the study. Screening or treating physicians had no access to the randomization list. 
Adverse events
AEs were recorded and evaluated daily during the hospitalization phase. At the rehabilitation visit, only surgical complications were recorded. Characterization of AEs included frequency, intensity/severity (categorized as 'mild', 'moderate', or 'severe'), and relation to the study drug ('related' or 'unrelated').
Statistical methods
We powered our study to detect a difference between the groups in the change in Hb from baseline of 0.5 g dl 21 ( 1) between days 4 and 30. Based on a predicted control group change of 0.5 (0.5), we required 51 cases per group (correlation between first and second measure was established to 0.6; 80% power; 5% significance level). Allowing for 15% loss to followup, we aimed to enrol 60 patients in each group. 
Results
Patient characteristics
Of 197 pre-recruited patients, 161 underwent surgery, and of those, 122 (75.8%) fulfilling the inclusion criteria were enrolled (60 FCM, 62 FS) and analysed according to the intention-totreat principle (Fig. 2) . Baseline patient characteristics, clinical characteristics, and preoperative PBM measures were comparable in the two treatment groups (Tables 1 and 2 
Perioperative evolution of Hb and iron status
Hb and haematocrit Before initiation of treatment, the preoperatively non-anaemic patients experienced a significant decrease in the mean Hb from 13.6 (0.9) g dl 21 at enrolment (day 230) to 10.5 (1.0) g dl 21 at 24 h after surgery (P,0.001 vs baseline; Table 3 ). The mean Hb further decreased to ,10.0 g dl 21 before it increased to ≥11.0 g dl 21 until the end of the study (day 30) in both groups.
At the end of the study period, a significantly higher proportion of FCM-than FS-treated patients had normal Hb levels (42.3% vs 23.5%; P¼0.04; n¼52 and 51 evaluable patients, respectively; Table 3 ). Notably, only 50% of FS-treated patients had Hb levels ≥10 g dl 21 at study end, whereas 50% in the FCM group had Hb levels ≥11.4 g dl 21 . The mean Hb increase from day 4 to day 30 and the rate of responders (Hb increase ≥1.5 g dl 21 ) were greater in the FCM group; yet, the differences were not statistically significant.
In the subset of patients with Hb levels ,10 g dl 21 at 24 h after surgery and available Hb levels at study end (n¼23), Hb increase until day 30 was significantly better with i.v. FCM compared with oral FS (P¼0.018) ( The mean haematocrit showed a similar time course to that of the Hb concentrations a decrease from preoperatively 41.6% to 31.5% at 24 h after surgery, followed by an increase to 35.7 (1.1)% (FCM) and 33.0 (1.4)% (FS) until day 30.
TSAT and serum ferritin
The mean TSAT increased significantly better until day 30 in FCM-compared with FS-treated patients (Table 3) . Notably, 87.5% in the FCM group compared with only 35.1% in the FS group achieved normal TSAT until the end of the study (P,0.001). Preoperative ferritin levels (Table 1) increased to significantly higher levels in the FCM than the FS group (Table 3) .
Patients with preoperatively low iron stores Overall, 56.7% (n¼68) of patients had a serum ferritin ,100 ng ml 21 at enrolment; 61.7% (n¼37) in the FCM and 51.7% (n¼31)
in the FS group. Among these patients, both Hb at day 30 and Hb increase from day 4 to day 30 were significantly higher with FCM than FS treatment (P¼0.01 and 0.03, respectively) ( 
Quality of life and physical performance
EQ-5D
The total EQ-5D score and most subscores were comparable between the treatment groups at enrolment (Table 1 ) and the end of the study period (Table 3) . Among preoperatively irondeficient patients (ferritin ,100 ng ml
21
), FCM treatment was associated with better scores for 'usual activities' and 'anxiety/ depression' at the end of the study period. Also, in patients with severe postoperative anaemia (Hb ,10.0 g dl 21 ), those with FCM treatment had better subscores for 'usual activities' at the end of the study period (1.91 vs 2.27; P¼0.04).
Barthel test and 6-MWT
Results of the Barthel test and the 6-MWT were similar between treatment groups at enrolment (Table 1 ) and at the end of the study period (Table 3) .
Iron exposure and tolerability of i.v. iron
The mean total i.v. iron dose was 884 (125) mg per patient. The theoretical oral iron dose was 2.4 g (100 mg daily from days 7 to 30). Overall, five patients (4%) received an allogeneic blood transfusion (Table 3 ). In each of the two groups, AEs were reported for 20% of patients (Table 4 ). The events were almost entirely mild to moderate, and none of the AEs was considered related to the study drug. Wound disturbances were the most frequent group of AEs followed by a transient increase in transaminases and urine infections without significant differences between the groups. One allergic reaction and one severe hypotension were reported in the control group and one swelling in the FCM group. The mean CRP levels were ,1 g dl 21 at all time points and at day 30, only one patient per group had CRP levels between 5 and 10 mg dl 21 . Serious, but unrelated, AEs comprised cholangitis in a patient with unknown Caroli syndrome and deep venous thrombosis in the FCM group and also a tibia fracture in the FS group. All serious AEs resolved with standard treatment.
Discussion
The results of this study confirm that non-anaemic patients undergoing TKA are at high risk of postoperative anaemia. The mean Hb of anaemic patients after operation receiving iron treatment improved between day 4 and day 30 postsurgery, particularly among FCM-treated patients with low baseline ferritin levels, low Hb levels, or both the day after surgery.
Over the recent years, preoperative anaemia has been accepted as risk factor for RBC transfusion, postoperative complications, and death. 1 4 8 Accordingly, the concept of perioperative PBM with a strong focus on treatment or prevention of preoperative anaemia has been developed. At our centre, a preoperative standard protocol including treatment with iron, subcutaneous erythropoietin, or both is applied and we have a very low transfusion rate in the range of 5%. However, even in centres dedicated to the prevention of preoperative anaemia, the risk of postoperative anaemia should not be underestimated. A recently presented study showed an 87% prevalence of postoperative anaemia among preoperatively non-anaemic patients who underwent knee surgery which compares well with the 75.8% at 24 h after surgery in our study. 20 Notably, 22 of the 33 non-randomized patients became anaemic the day after randomization. The fact that more than half of the non-anaemic patients in this study were iron-deficient at enrolment (TSAT ,20% or ferritin ,100 ng ml 21 ) emphasizes that serious assessment and management of patients' iron status should be as important as Hb management. Among available iron administration routes, i.v. iron treatment is characterized by high utilization of administered iron and good tolerability allowing the administration of high single doses. 33 Thus, i.v. iron is the preferred option for rapid iron repletion in patients with large iron deficits, chronic diseases, or both where oral iron is ineffective due to poor absorption or inflammation-related iron sequestration (or both). Accordingly, this study showed significantly better improvements in the iron parameters TSAT and serum ferritin of i.v. FCM-treated patients compared with oral FS-treated patients. The higher proportion of iron-deficient patients in the oral than the i.v. iron group (65% vs 12.5%) could be a reason for the significant difference in platelet counts at day 30. This would be in line with discussions about a link between iron deficiency and thrombocytosis in different patient populations. Table 4 AEs profile. Data shown as number of events and per cent of patients; no significant differences between the frequencies of shown AE categories between the study groups. *'Control' group comprises the FS group; however, AEs not related to surgical complications were recorded only during the hospitalization phase (i.e. before initiation of FS). AE, adverse event; SAE, serious adverse event Furthermore, patients with preoperatively low iron stores experienced significantly better Hb increase with FCM than oral treatment. Moreover, 40% of FCM-treated iron-deficient patients compared with only 8% of FS-treated iron-deficient patients achieved normal Hb levels. Iron-deficient patients who developed postoperative anaemia with Hb levels below 10 g dl 21 showed particular benefit from FCM; yet, the number of patients in this subgroup was already quite low. Notably, the low number of patients with both iron deficiency and severe postoperative anaemia might result from the thorough PBM programme established at our centre and should not be generalized. Conversely, this result shows that two easily available measures, preoperative serum ferritin and postoperative Hb, allow identification of patients that may benefit most from an i.v. iron administration after surgery. Few published studies investigated the use of i.v. iron for the correction of postoperative anaemia and improvement of performance and quality of life. 23 25 32 37 38 However, most of them are retrospective observational studies focusing on the reduction in RBC transfusions in patients with severe anaemia and no preoperative blood management. Owing to the established PBM programme in our centre, it would require very large patient numbers to identify potential additional treatment effects on the RBC transfusions rate. Despite patients not being blinded to the study treatment, overall quality-of-life scores neither changed over the study period nor differed between treatment groups. Significant differences in the EQ-5D subcategories, 'usual activities' and 'anxiety/depression', are meaningful for the patient's selfesteem and subjective well-being. The aim of performing the 6-MWT was to characterize the study population more than to assess physical performance in response to iron. In general, selection and timing of this performance test should be reconsidered in studies involving this type of surgery.
-36
Postoperative i.v. iron treatment was generally well tolerated and reported AEs primarily related to the surgical procedure or patients' comorbidities and not to the iron treatment. Notably, AEs were recorded only during the hospitalization phase, that is, before the initiation of oral iron treatment. Since the rehabilitation visit on day 30 focused on the orthopaedic outcomes and wound disturbances, patient complaints of gastrointestinal discomfort (expected in the oral iron group) were not recorded systematically. The absence of allergic reactions in the FCM group confirms the low immunogenicity of non-dextran iron preparations. 39 40 No systemic inflammation has been observed and the aetiology of observed urinary tract infections remained unclear. Disturbances in wound healing were not significantly different between the treatment groups, but our study was underpowered to properly evaluate this outcome. No hypersensitivity reactions and no new safety findings were identified in the FCM group.
Conclusions
Patients undergoing TKA in a centre with an established PBM programme that corrects or prevents most cases of preoperative anaemia are still at high risk of postoperative anaemia.
Therefore, both postoperative Hb and preoperative iron status should be routinely assessed in TKA and probably elective orthopaedic surgery in general. Postoperative FCM treatment resulted in more frequent correction of postoperative anaemia than oral iron. Patients with low iron stores before surgery, with significant postoperative anaemia the day after surgery, or both showed particular benefit of i.v. over oral iron, thus supporting the use of FCM in postoperative patient management.
